Tesamorelin: The Complete Guide
The only peptide FDA-approved specifically to reduce visceral fat — the deep, dangerous belly fat around your organs. Here's how it works, what the research shows, and what to know.
This guide summarizes published clinical research on tesamorelin. It is educational only and not a substitute for advice from a qualified healthcare professional. Sources are listed at the end.
Most fat-loss compounds work on your appetite or your whole body at once. Tesamorelin is different — it's the one peptide with genuine FDA approval to target a specific, dangerous kind of fat: the visceral fat packed deep around your internal organs. That precision, backed by real human trials, is what makes it stand out in the metabolic space.
This guide explains what tesamorelin is, how its clever mechanism works, what the clinical research actually demonstrated, how it's used, and how it compares to other growth-hormone peptides and to the GLP-1 weight-loss drugs — all grounded in the published evidence.
What Tesamorelin Is
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH) — a synthetic version of a natural hormone your body already uses. Under the brand name Egrifta, it was FDA-approved in 2010 to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy (a condition involving abnormal fat distribution).
The natural hormone it copies, GHRH, is what your hypothalamus uses to tell your pituitary gland to release growth hormone. The problem with natural GHRH is that it breaks down almost instantly. Tesamorelin solves this with a small structural modification (a trans-3-hexenoic acid group) that resists rapid breakdown — so it survives long enough to do its job of triggering a proper growth-hormone pulse.
The important distinction: it's not growth hormone
Tesamorelin does not inject growth hormone into your body. Instead, it signals your own pituitary gland to release your own growth hormone, in your body's natural pulsing pattern. This is a crucial difference from injecting synthetic HGH directly: because tesamorelin works through your natural system, your body's own feedback controls stay intact — so it doesn't shut down your natural production or flood you with constant high growth-hormone levels. It restores a natural rhythm rather than overriding it.
How It Works
The mechanism runs in a simple chain, from injection to fat loss:
1. Signals the Pituitary
Injected under the skin, tesamorelin travels to your pituitary gland and binds GHRH receptors, prompting it to release a natural pulse of growth hormone.
2. Growth Hormone Rises
Your pituitary releases your own growth hormone in a natural, pulsing pattern — peaking roughly 30–60 minutes after injection, not as a constant flood.
3. The Liver Makes IGF-1
That growth hormone signals your liver to produce IGF-1 (insulin-like growth factor-1), the molecule that carries out most of growth hormone's downstream effects.
4. Visceral Fat Breaks Down
The rise in growth hormone and IGF-1 drives lipolysis (fat breakdown), preferentially in the deep visceral fat around your organs.
The key feature is that short half-life doesn't matter the way you'd think. Tesamorelin itself clears from the blood in around 26 minutes — but that's not the point. What matters is the downstream rise in growth hormone and IGF-1 that it triggers, which lasts far longer and builds up with consistent daily use over days and weeks. You're not dosing for the peptide to linger; you're dosing to set off a natural hormone cascade.
Why It Targets Belly Fat Specifically
One of the most interesting things about tesamorelin is its selectivity. It doesn't just reduce fat everywhere — it preferentially mobilizes visceral fat (the deep fat around the organs) while largely sparing subcutaneous fat (the pinchable fat under the skin). Why?
The answer lies in how different fat behaves. Visceral fat and subcutaneous fat differ in how they respond to growth hormone signaling — the visceral fat depot is more responsive to the lipolytic (fat-breaking) effects that growth hormone and IGF-1 drive. So when tesamorelin raises those hormones, the deep visceral fat responds more strongly than the subcutaneous fat does.
Why this matters so much
Visceral fat is the metabolically dangerous kind — it's linked to insulin resistance, heart disease, and fatty liver, and it's often stubbornly resistant to ordinary dieting. A compound that specifically targets it, while sparing muscle and even the subcutaneous fat, is genuinely valuable. This is exactly why tesamorelin occupies a unique niche: it's not a general weight-loss tool, it's a visceral-fat specialist. For the bigger picture, see our guide on peptides for belly fat & visceral fat.
What the Research Shows
Tesamorelin stands apart from most research peptides because its evidence comes from large, randomized, placebo-controlled human trials — the gold standard — not just anecdotes or animal studies.
Visceral Fat Reduction
In the pivotal Phase 3 trials (published in the New England Journal of Medicine, involving hundreds of patients), tesamorelin at 2 mg daily reduced visceral fat by roughly 15–18% over about 6 months, compared to placebo. Some patients achieved reductions exceeding 20%. Importantly, MRI measurements confirmed the loss was preferentially visceral — the deep fat — while subcutaneous fat was relatively spared.
Liver Fat & Metabolic Markers
Beyond visceral fat, research has shown tesamorelin reduces liver fat meaningfully (a study reported around a 37% relative reduction in liver fat), which is significant given how closely visceral fat and fatty liver are linked. It also tends to preserve or slightly increase lean muscle mass — an unusual and welcome profile, since many fat-loss approaches sacrifice muscle.
An honest note on the evidence
Tesamorelin's strongest trial evidence comes specifically from people with HIV-associated lipodystrophy — the population it was approved for. Its use for general visceral fat in other people is off-label and less thoroughly studied in large trials, even though the underlying mechanism applies broadly and it's increasingly used this way. This is worth understanding honestly: the mechanism is well-validated, but extrapolating the exact trial numbers to the general population involves some assumption.
Benefits Beyond Fat
Because tesamorelin raises growth hormone and IGF-1 through natural pathways, users and researchers have noted effects beyond visceral fat reduction — the general benefits associated with healthy growth-hormone signaling:
- Body composition — preserving or slightly building lean muscle while reducing fat
- Recovery and tissue repair — growth hormone and IGF-1 support these processes
- Sleep quality — some report improved sleep, and much natural growth-hormone release happens during deep sleep
- Cognitive effects — some research has explored tesamorelin's effects on cognition, with early interest in this area
These are secondary to its core visceral-fat role, and the evidence for them varies in strength — but they reflect the broad reach of the growth-hormone axis it activates.
Dosing & Use
The following reflects the standard approach from clinical use and labeling. It is a general informational reference, not a medical recommendation.
| Aspect | Typical Approach |
|---|---|
| Standard dose | 2 mg subcutaneously, once daily |
| Timing | At bedtime — aligns with the body's natural nighttime growth-hormone release |
| Route | Subcutaneous injection (into the fat, usually the abdomen) |
| Time to results | Visceral fat changes build over ~26 weeks, not days |
| Consistency | Daily use matters — the IGF-1 benefit accumulates over time |
Why bedtime, and why daily
Tesamorelin is dosed at night because that's when your body naturally releases the most growth hormone — so it works with your natural rhythm rather than against it. And it's daily because, unlike some longer-acting peptides, its benefit comes from consistently triggering that nightly pulse; the IGF-1 elevation builds gradually with steady use. Patience matters: the visible visceral-fat changes in trials appeared over about six months, not in the first few weeks.
Tesamorelin is supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic water before injection. See our reconstitution guide, dosing basics, and — given the climate here — our tropical storage guide, since GHRH peptides are heat-sensitive.
Side Effects & Monitoring
Because tesamorelin works through your natural growth-hormone system, its side effects are largely those of raised growth hormone and IGF-1. Most are mild, but a few warrant genuine attention and monitoring.
Common
- Injection-site reactions — redness, itching, or irritation (the most common)
- Joint pain (arthralgia) and muscle aches
- Fluid retention — mild swelling/edema, sometimes puffiness
- Tingling or numbness (paresthesia), sometimes carpal-tunnel-type symptoms in the hands
Requires Monitoring
- IGF-1 levels — since tesamorelin raises IGF-1, levels should be checked periodically (often every ~6 months) and the compound reconsidered if they climb too high
- Blood sugar / glucose tolerance — growth hormone can raise blood sugar, so glucose and HbA1c are worth monitoring, especially for anyone with or at risk of diabetes
The monitoring point matters
Tesamorelin's two effects that need watching are elevated IGF-1 and its potential to raise blood sugar. These are manageable with periodic blood work (IGF-1, fasting glucose, HbA1c), but they're a real reason this compound is best used with medical oversight rather than blindly. Anyone with diabetes, prediabetes, or glucose concerns should be especially cautious and involve a doctor. See our when to consult a doctor guide.
How It Compares
Tesamorelin vs Other Growth Hormone Peptides
Tesamorelin sits alongside other GH-stimulating peptides like sermorelin and CJC-1295, but with distinct advantages for fat loss.
| Tesamorelin | Sermorelin | CJC-1295 | |
|---|---|---|---|
| Structure | Full GHRH (1-44), stabilized | GHRH fragment (1-29) | Modified GHRH analog |
| Fat-loss evidence | Strongest (FDA-approved for visceral fat) | Modest | Modest |
| IGF-1 response | Strong | Gentler | Strong, longer-acting |
| Best for | Visceral fat specifically | Gentle GH support, anti-aging | Sustained GH elevation |
In short, tesamorelin is the choice when the specific goal is visceral fat reduction with real clinical backing; sermorelin and CJC are gentler, more general GH-support options. Our Sermorelin vs CJC vs Tesamorelin comparison covers this in depth.
Tesamorelin vs GLP-1s (Semaglutide, Tirzepatide)
This is a common and important question. The two work completely differently and are best seen as complementary, not competing:
- GLP-1s (semaglutide, tirzepatide) reduce total body fat through appetite suppression — powerful for overall weight loss.
- Tesamorelin targets visceral fat specifically and preserves muscle, without suppressing appetite.
A common scenario: someone loses significant weight on a GLP-1 but still has a stubborn ring of deep belly fat — precisely what tesamorelin is designed to address. They can even be complementary tools for different jobs. See our GLP-1 comparison guide for the appetite-based options.
Safety & Who Should Avoid It
Tesamorelin has a well-characterized safety profile from its clinical trials and years of approved use, but it has clear contraindications that must be respected.
Who should not use tesamorelin
Tesamorelin is contraindicated in anyone with active cancer or a history of certain cancers — because raising growth hormone and IGF-1 could theoretically promote tumor growth. It's also contraindicated in pregnancy, and in people with pituitary problems (such as after pituitary surgery or radiation, or with hypopituitarism), since it depends on a working pituitary. It should be used cautiously by anyone with diabetes or glucose intolerance (it can raise blood sugar). Anyone with a history of cancer, diabetes, or a pituitary condition must consult a doctor before considering it.
For the broader safety picture across compounds, see our guides on drug interactions and whether peptides are safe.
Common Questions
What is tesamorelin used for?
Tesamorelin is FDA-approved to reduce excess visceral abdominal fat (the deep fat around the organs) in adults with HIV-associated lipodystrophy. Beyond that approved use, it's used off-label for general visceral fat reduction, body composition, and the benefits associated with healthy growth-hormone signaling. Its standout quality is that it specifically targets visceral fat while sparing muscle — a rare and valuable profile.
How is tesamorelin different from growth hormone (HGH)?
This is the key distinction. Tesamorelin doesn't inject growth hormone — it signals your own pituitary to release your own growth hormone naturally. This keeps your body's feedback controls intact, so it doesn't shut down your natural production or create constant sky-high hormone levels the way injecting synthetic HGH can. It works with your natural rhythm rather than overriding it, which gives it a gentler, more self-regulating safety profile than direct HGH.
How much visceral fat can tesamorelin reduce?
In the pivotal Phase 3 trials, tesamorelin at 2 mg daily reduced visceral fat by roughly 15–18% over about six months, with some people exceeding 20%. MRI confirmed the loss was preferentially visceral (the deep fat) while subcutaneous fat was relatively spared. It also reduced liver fat meaningfully. Bear in mind these figures come from trials in a specific population (HIV lipodystrophy), so general-use results may vary.
How long does tesamorelin take to work?
Patience is required. The visible visceral-fat changes in clinical trials appeared over roughly 26 weeks (about six months), not in the first few weeks. This is because the benefit comes from the gradual accumulation of raised IGF-1 with consistent daily use, rather than an immediate effect. It's a slow-and-steady compound, so consistency over months is what the results are built on.
Why is it dosed at night?
Tesamorelin is taken at bedtime because that's when your body naturally releases the most growth hormone. Dosing then works with your natural rhythm, reinforcing the nighttime growth-hormone pulse rather than fighting your biology. It's also dosed daily because its benefit comes from consistently triggering that natural pulse — the IGF-1 elevation builds up gradually with steady, ongoing use.
Can I use tesamorelin with a GLP-1 like semaglutide?
They're often described as complementary because they work differently: GLP-1s reduce total fat through appetite suppression, while tesamorelin specifically targets visceral fat and preserves muscle without affecting appetite. A common scenario is someone who's lost significant weight on a GLP-1 but still has stubborn deep belly fat — exactly what tesamorelin addresses. Combining compounds should always involve a healthcare professional, especially since both can affect blood sugar.
What are the main things to monitor?
Two things: IGF-1 levels (since tesamorelin raises them, they should be checked periodically) and blood sugar (growth hormone can raise glucose, so fasting glucose and HbA1c are worth watching, especially with diabetes risk). These are manageable with periodic blood work, but they're the reason tesamorelin is best used with medical oversight. It's also contraindicated in active cancer, pregnancy, and pituitary conditions.
Is tesamorelin legal in Costa Rica?
Tesamorelin is sold as a research compound in Costa Rica, the same framework used in most countries with active peptide markets, for laboratory and research purposes. Buying locally avoids the heat exposure that international shipping puts delicate, heat-sensitive GHRH peptides through. See our FAQ page for more.
Questions about tesamorelin?
Whether you want to understand how it targets visceral fat, how it compares to GLP-1s or other GH peptides, or how it's used, reach out. We answer every message personally — no pressure, no upsell.
Contact Us on WhatsAppImportant disclaimer: The information in this guide is general educational content only. It is not medical advice, a prescription, or a personalized recommendation. Tesamorelin is FDA-approved (as Egrifta) to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy when prescribed by a licensed clinician; use for general visceral fat is off-label and less studied in large trials. Research-grade tesamorelin is sold as a research compound intended for laboratory and scientific study, not as a substitute for prescribed, medically supervised treatment. Tesamorelin is contraindicated in active malignancy, pregnancy, and pituitary conditions, raises IGF-1, and can affect blood sugar — requiring monitoring. Always consult a qualified healthcare professional before beginning any peptide protocol, especially if you have a history of cancer, diabetes, or a pituitary condition. Products sold by Peptides Costa Rica are intended for laboratory and research purposes only.
- New England Journal of Medicine (Falutz et al., 2007): Tesamorelin and visceral adipose tissue reduction in HIV-associated lipodystrophy.
- New England Journal of Medicine (2010): Phase 3 tesamorelin trial (404 patients) — ~18% visceral fat reduction at 2 mg/day.
- The Lancet HIV / JAMA (Stanley et al., 2019): Tesamorelin and reduction of liver fat (~37% relative) and fibrosis progression.
- FDA Prescribing Information: Egrifta / Egrifta SV (tesamorelin) — dosing, monitoring, contraindications, and warnings.
- NCBI/PMC: GHRH analogs — mechanism, pulsatile GH release, and IGF-1 signaling.
- Obesity Research & Clinical Practice (2026): Systematic review and meta-analysis of tesamorelin on body composition.
- Nature Reviews Drug Discovery: "Therapeutic peptides: current applications and future directions."
